Revised MenACWY Vaccination Strategy for Adolescents in Germany
G-BA Approves MenACWY Vaccination Strategy Shift for Adolescents
Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA) has approved key amendments to the Protective Vaccination Directive on December 18, 2025, implementing STIKO recommendations. This MenACWY vaccination strategy discontinues routine meningococcal serogroup C (MenC) vaccination at 12 months for infants and introduces quadrivalent MenACWY as the standard primary vaccination for adolescents aged 12-14, with catch-up up to age 24. The changes follow STIKO’s evaluation in Epidemiological Bulletin 44/2025, addressing epidemiological shifts for optimal protection.
Rising Serogroup Y Threat Reshapes Strategy
STIKO data reveals a pivotal change in invasive meningococcal disease (IMD) patterns, driving the MenACWY vaccination strategy. MenC cases dropped from 0.05 to 0.01 per 100,000 between 2015 and 2024, while serogroup Y surged from 0.02 to 0.14 per 100,000, peaking in adolescents. Modeling shows adolescent MenACWY dosing outperforms infant MenC vaccination by curbing carriage and delivering herd protection, minimizing IMD morbidity, hospitalizations, and deaths from serogroups A, C, W, and Y. Infant MenACWY is not routinely recommended due to low post-12-month risk.
Procedural Steps Align Directive with STIKO
Under § 20i SGB V, G-BA must adopt STIKO advice within two months. Amendments delete MenC basic immunization from Annex 1 (vaccination calendar) and Annex 2 (codes), adding MenACWY standard vaccination for ages 12-14 and updating code 89114 to 89140. The process involved provider consultations, GKV-Spitzenverband input, patient groups, Unterausschuss consensus on November 11, 2025, and a brief comment period ending December 2, 2025, with no new reporting burdens.
Cost-Efficient Herd Immunity Gains
This MenACWY vaccination strategy boosts targeting adolescents for carriage reduction and herd effects, cutting long-term IMD costs without infant schedule expansions. Reimbursement covers standard and catch-up doses to age 24, prompting provider updates but no supply changes in Annex 3. It exemplifies evidence-based § 20i SGB V updates, protecting infants indirectly at lower systemic cost.
